Texas Permanent School Fund Gilead Sciences, Inc. Transaction History

Texas Permanent School Fund

$597 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$63.15 - $72.88 $3.27 Million - $3.77 Million	-51,724 Reduced 20.08%	205,928 $14.1 Million
Q1 2024 May 03, 2024	BUY	$71.58 - $87.29 $20,758 - $25,314	290 Added 0.11%	257,652 $18.9 Million
Q4 2023 Feb 08, 2024	SELL	$73.27 - $83.09 $13,701 - $15,537	-187 Reduced 0.07%	257,362 $20.8 Million
Q3 2023 Nov 09, 2023	SELL	$73.94 - $80.67 $303,301 - $330,908	-4,102 Reduced 1.57%	257,549 $19.3 Million
Q2 2023 Aug 07, 2023	BUY	$76.01 - $86.7 $127,164 - $145,049	1,673 Added 0.64%	261,651 $20.2 Million
Q1 2023 May 01, 2023	BUY	$77.31 - $88.08 $6.32 Million - $7.2 Million	81,775 Added 45.89%	259,978 $21.6 Million
Q4 2022 Feb 07, 2023	BUY	$62.32 - $89.47 $53,595 - $76,944	860 Added 0.48%	178,203 $15.3 Million
Q3 2022 Oct 25, 2022	BUY	$59.54 - $68.01 $694,593 - $793,404	11,666 Added 7.04%	177,343 $10.9 Million
Q2 2022 Aug 08, 2022	BUY	$57.72 - $65.01 $171,601 - $193,274	2,973 Added 1.83%	165,677 $10.2 Million
Q1 2022 May 06, 2022	SELL	$57.92 - $72.58 $582,733 - $730,227	-10,061 Reduced 5.82%	162,704 $9.67 Million
Q4 2021 Feb 08, 2022	SELL	$64.88 - $73.64 $1.36 Million - $1.54 Million	-20,929 Reduced 10.81%	172,765 $12.5 Million
Q3 2021 Oct 28, 2021	SELL	$67.69 - $73.03 $992,403 - $1.07 Million	-14,661 Reduced 7.04%	193,694 $13.5 Million
Q2 2021 Jul 27, 2021	SELL	$63.47 - $69.35 $93,554 - $102,221	-1,474 Reduced 0.7%	208,355 $14.3 Million
Q1 2021 May 03, 2021	SELL	$60.0 - $68.46 $671,100 - $765,725	-11,185 Reduced 5.06%	209,829 $13.6 Million
Q4 2020 Feb 04, 2021	SELL	$56.65 - $64.55 $832,075 - $948,110	-14,688 Reduced 6.23%	221,014 $12.9 Million
Q3 2020 Nov 06, 2020	BUY	$62.1 - $78.08 $914,733 - $1.15 Million	14,730 Added 6.67%	235,702 $14.9 Million
Q2 2020 Aug 04, 2020	SELL	$72.34 - $84.0 $659,017 - $765,240	-9,110 Reduced 3.96%	220,972 $17 Million
Q1 2020 Apr 27, 2020	BUY	$62.63 - $80.22 $389,433 - $498,807	6,218 Added 2.78%	230,082 $17.2 Million
Q4 2019 Feb 03, 2020	SELL	$61.62 - $67.78 $742,089 - $816,274	-12,043 Reduced 5.1%	223,864 $14.5 Million
Q3 2019 Oct 31, 2019	SELL	$62.51 - $69.0 $582,155 - $642,597	-9,313 Reduced 3.8%	235,907 $15 Million
Q2 2019 Aug 09, 2019	SELL	$61.87 - $69.38 $180,784 - $202,728	-2,922 Reduced 1.18%	245,220 $16.6 Million
Q1 2019 May 02, 2019	SELL	$62.53 - $70.05 $753,674 - $844,312	-12,053 Reduced 4.63%	248,142 $16.1 Million
Q4 2018 Feb 11, 2019	SELL	$60.54 - $79.0 $1.87 Million - $2.43 Million	-30,818 Reduced 10.59%	260,195 $16.3 Million
Q3 2018 Oct 22, 2018	SELL	$71.28 - $78.92 $1.87 Million - $2.07 Million	-26,282 Reduced 8.28%	291,013 $22.5 Million
Q2 2018 Jul 23, 2018	SELL	$64.88 - $75.68 $1.37 Million - $1.6 Million	-21,173 Reduced 6.26%	317,295 $22.5 Million
Q1 2018 Apr 20, 2018	SELL	$72.84 - $88.8 $1.32 Million - $1.61 Million	-18,131 Reduced 5.08%	338,468 $25.5 Million
Q4 2017 Jan 23, 2018	SELL	$71.15 - $83.52 $377,948 - $443,658	-5,312 Reduced 1.47%	356,599 $25.5 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $26.1 Million - $30.9 Million	361,911	361,911 $29.3 Million

Others Institutions Holding GILD

# of Institutions

1,931

Shares Held

991M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$10.8 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.4 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$6.88 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.55 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.41 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

News

Stay updated on Texas Permanent School Fund with notifications on news.

Account